drugset / Trial / NCT00003215

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

NCT00003215

Phase 3 Completed 400 enrolled Swiss Cancer Institute
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells. It is not known whether receiving standard combination chemotherapy alone is more effective than receiving multiple combination chemotherapy plus peripheral stem cell transplantation for aggressive non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing giving different combination chemotherapy regimens together with peripheral stem cell transplantation to see how well they work in treating patients with newly diagnosed aggressive non-Hodgkin's lymphoma.

Timeline

Start
1997-04
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject Melphalan Small molecule Intravenous
Subject Methotrexate Small molecule Intravenous
Subject Methylprednisolone Other / unclassified Intravenous
Subject Mitoxantrone Small molecule Intravenous
Subject Prednisone Other / unclassified Oral
Subject Vincristine Small molecule Intravenous
Background Cytarabine Small molecule Intrathecal
Background Hydrocortisone Other / unclassified Intrathecal
Background Leucovorin Small molecule Intravenous
Background filgrastim Protein / enzyme biologic Subcutaneous

Indications